Navigate Fool.com
Will NBIX beat
the market?
Community Rating: 3 Stars: Appealing

13.83 0.12 (0.88%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $13.72
Previous Close $13.71
Daily Range $13.54 - $13.89
52-Week Range $8.57 - $20.29
Market Cap $1.0B
P/E Ratio -20.16
Dividend (Yield) $0.00 (0.0%)
Volume 161,951
Average Daily Volume 521,736
Current FY EPS -$0.78

How do you think NBIX
will perform against the market?

Top NBIX Bull/Bear Pitches


CellBlock9 (< 20)
Submitted February 7, 2014

S&P 5 star, 16.12

0 Replies Reply Report this Post

zzlangerhans (< 20)
Submitted September 10, 2012

Neurocrine has been turning in solid pipeline progress for several years now but they haven't had much success holding gains in the share price. Now that the phase III trial of elagolix is in progress … More

0 Replies Reply Report this Post

News & Commentary

Will These 3 Drugs Keep AbbVie's Future Bright After Humira?

While generic drugmakers will have a whale of a challenge creating a biosimilar of AbbVie's star drug Humira, this big pharma's thinking ahead with three up-and-coming drugs developing in its pipeline.

Neurocrine Biosciences (NBIX) Shares Cross Below 200 DMA

Can You Still Ride This Month's 3 Biggest Winners To Greater Gains?

Biotech dominates in January as Intercept, Cell Therapeutics, and Neurocrine all surge after good drug-trial news.

Piper Jaffray’s Seven Biotech Stocks to Buy With Huge Potential Upside

3 Stocks to Get on Your Watchlist

A big-box retail giant, an up-and-coming developer of a tardive dyskinesia treatment, and a short-sale candidate.

This Week in Biotech: Putting On a Clinic

In part one of This Week in Biotech we're looking at four encouraging clinical trials, including a company that gained 545%, as well as an announced collaboration and a buyout.

3 Humongous Health-Care Stocks This Week

Intercept Pharmaceuticals, Neurocrine Biosciences, and Epizyme achieve stunning gains in a great week for health-care investors.

Neurocrine Biosciences Inc. Nearly Doubles (but Not Really)

Neurocrine Biosciences isn't up nearly as much as it appears.

Why Neurocrine Biosciences, Epizyme, and Plug Power Are Today's 3 Best Stocks

The S&P 500 delivers its first gain of the year while Neurocrine Biosciences, Epizyme, and Plug Power all rocket higher by at least 39%!

Mid-Afternoon Market Update: Markets Post Large Rally as Textron Falls on Citron Report

See More NBIX News...





Neurocrine Biosciences, Inc. (NBIX) Description

Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis. Website: http://www.neurocrine.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks